Latest Information Update: 14 Feb 2006
At a glance
- Originator ZymoGenetics
- Class Anti-ischaemics
- Mechanism of Action Opioid delta receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Myocardial ischaemia
Most Recent Events
- 14 Feb 2006 No development reported - Preclinical for Myocardial ischaemia in USA (unspecified route)
- 23 Sep 2002 This compound is still in active development
- 30 Nov 2000 New profile